Literature DB >> 18208808

Clinical outcomes of ABO-incompatible RBC transfusions.

Kim A Janatpour1, Norman D Kalmin, Hanne M Jensen, Paul V Holland.   

Abstract

Factors that predict outcome after ABO-incompatible RBC transfusions are not well defined. We studied whether the volume of incompatible blood transfused would determine the signs and symptoms and survival outcome for ABO-incompatible RBC transfusions. We reviewed ABO-incompatible RBC transfusions from our institutions and our consultations for 35 years and from a survey of America's Blood Centers' members regarding causes, volume, signs, symptoms, and outcomes of ABO-incompatible RBC transfusions in their service areas from 1995 through 2005. All ABO-incompatible transfusions were due to error; 26 (62%) of 42 occurred at the patient's bedside. Of 36 patients who received more than 50 mL of incompatible blood, 23 (64%) manifested signs or symptoms related to the incompatible transfusion, and 6 (17)% died. Only 3 (25%) of 12 patients who received 50 mL or less of incompatible blood had associated signs or symptoms, and none died. Hypotension, hemoglobinuria, and/or hemoglobinemia were the most frequent findings in survivors and patients who died.ABO-incompatible RBC transfusion does not inevitably mean death or even occurrence of symptoms. Prompt recognition and discontinuation of the transfusion are critical because transfusing less ABO-incompatible blood may minimize signs and symptoms and may prevent death.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18208808     DOI: 10.1309/VXY1ULAFUY6E6JT3

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  18 in total

1.  Clinically significant adverse events after major ABO mismatch BMT.

Authors:  R S Nickel; E K Waller; M Qayed; K-Y Chiang
Journal:  Bone Marrow Transplant       Date:  2015-10-05       Impact factor: 5.483

2.  A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation.

Authors:  Kathryn R Girard-Pierce; Sean R Stowell; Nicole H Smith; C Maridith Arthur; Harold C Sullivan; Jeanne E Hendrickson; James C Zimring
Journal:  Blood       Date:  2013-07-22       Impact factor: 22.113

Review 3.  Pathogenesis and mechanisms of antibody-mediated hemolysis.

Authors:  Willy A Flegel
Journal:  Transfusion       Date:  2015-07       Impact factor: 3.157

4.  Fully automated, clinical-grade bone marrow processing: a single-centre experience.

Authors:  Benedetta Mazzanti; Serena Urbani; Simone Dal Pozzo; Paola Bufano; Lara Ballerini; Alessia Gelli; Irene Sodi; Irene Donnini; Massimo Di Gioia; Stefano Guidi; Julien Camisani; Riccardo Saccardi
Journal:  Blood Transfus       Date:  2016-09-27       Impact factor: 3.443

Review 5.  Transfusion Support for ABO-Incompatible Progenitor Cell Transplantation.

Authors:  Patricia M Kopko
Journal:  Transfus Med Hemother       Date:  2015-10-29       Impact factor: 3.747

6.  Severe Acute Hemolytic Transfusion Reaction Treated with Ruxolitinib and Plasma Exchange.

Authors:  Burak Deveci; Rabin Saba; Husnu Altunay; Tayfur Toptas; George Kublashvilli; Ihsan Karadogan
Journal:  Transfus Med Hemother       Date:  2021-01-08       Impact factor: 3.747

7.  A novel peptide inhibitor of classical and lectin complement activation including ABO incompatibility.

Authors:  Clifford T Mauriello; Haree K Pallera; Julia A Sharp; Jon L Woltmann; Shizhi Qian; Pamela S Hair; Pieter van der Pol; Cees van Kooten; Nicole M Thielens; Frank A Lattanzio; Kenji M Cunnion; Neel K Krishna
Journal:  Mol Immunol       Date:  2012-08-18       Impact factor: 4.407

Review 8.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

9.  Use of an identification system based on biometric data for patients requiring transfusions guarantees transfusion safety and traceability.

Authors:  Francesco Bennardello; Carmelo Fidone; Sergio Cabibbo; Salvatore Calabrese; Giovanni Garozzo; Grazia Cassarino; Agostino Antolino; Giuseppe Tavolino; Nuccio Zisa; Cadigia Falla; Giuseppe Drago; Giovanna Di Stefano; Pietro Bonomo
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

Review 10.  Examining the Role of Complement in Predicting, Preventing, and Treating Hemolytic Transfusion Reactions.

Authors:  Connie M Arthur; Satheesh Chonat; Ross Fasano; Marianne E M Yee; Cassandra D Josephson; John D Roback; Sean R Stowell
Journal:  Transfus Med Rev       Date:  2019-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.